Ongoing Clinical Trials for Japanese Encephalitis
Currently, there is 1 ongoing clinical trial investigating vaccination strategies for Japanese Encephalitis, also known as Encephalitis Japanese B. This trial is exploring alternative methods of administering the IXIARO vaccine to improve protection against this mosquito-borne viral infection that affects the brain.
Clinical trial locations
Study on Immune Response to Intradermal Ixiaro Vaccine in Healthy Adults Aged 18-64
This trial is investigating whether the IXIARO vaccine can be effectively administered into the skin (intradermally) rather than through the traditional muscle injection (intramuscularly). The vaccine is designed to protect against this viral infection that affects the brain and is transmitted through mosquito bites.
Who can participate:
- Adults between 18 and 64 years old
- People in general good health, confirmed through medical history and physical examination
- Individuals who have never received a vaccination for this disease before
- Women of childbearing age who agree to use reliable birth control methods during the study
- People who can attend all scheduled study visits
- Those willing to provide written informed consent after understanding the study procedures
Who cannot participate:
- People younger than 18 or older than 64 years
- Individuals who are not in good general health
- Members of vulnerable populations who may require special protection or care
What the trial involves:
The main goal of this study is to determine whether giving the IXIARO vaccine through the skin produces an immune response as strong as the traditional muscle injection method. Researchers will measure this by checking the levels of neutralizing antibodies in participants’ blood. Antibodies are proteins your immune system creates to fight infections.
Participants will receive a single dose of the vaccine administered into the skin. Throughout the study, researchers will monitor the immune response by examining antibody levels and observing certain immune cells. They will also track any side effects that participants may experience.
Investigational vaccine:
IXIARO is the vaccine being tested in this trial. It works by stimulating your body’s immune system to produce antibodies that can neutralize the virus and prevent infection. The study specifically examines whether administering this vaccine into the skin can be as effective as the standard muscle injection, which could potentially offer a more efficient delivery method, especially in areas where the disease is common.
The trial is expected to continue until the end of 2029, with findings aimed at improving vaccination strategies against this serious disease.
Summary
This single ongoing trial is being conducted in Finland and focuses exclusively on optimizing the administration method for the IXIARO vaccine. The research represents an important step in potentially making vaccination more accessible and efficient. By investigating whether intradermal administration can match the effectiveness of intramuscular injection, researchers hope to provide healthcare providers with more flexible options for protecting people against this mosquito-borne viral infection. The study’s lengthy timeline through 2029 reflects the careful monitoring needed to fully understand both the immune response and safety profile of this alternative vaccination approach.